Abstract
It is known that the renin-angiotensin system (RAS) plays a fundamental role not only as a vasoconstrictor incontrolling blood pressure and electrolyte/fluid homeostasis, but also as a mitogenic factor through the Ang-II type-1(AT1) receptor in smooth muscle cells and cardiac myocytes. Angiotensin II (Ang-II) is indeed thought to be a growthfactor, and Ang-II receptor blockers (ARBs), a class of antihypertensive agent, suppress signal transduction pathwaysmediated by several growth factors or cytokines, through the AT1 receptor. There is increasing evidence that the RAS isimplicated in the development of various cancers. We previously demonstrated that ARBs have the potential to inhibit thegrowth of prostate cancer cells and tumors through the AT1 receptor. This review highlights the possibility of ARBs asnovel agents for prostate cancer as well as other cancers, and reviews the literature on this area.
Keywords: Angiotensin II, renin-angiotensin system, angiotensin II receptor blocker, prostate cancer, hormone-refractorycancer
Mini-Reviews in Medicinal Chemistry
Title: Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Volume: 6 Issue: 7
Author(s): Hiroji Uemura, Hitoshi Ishiguro and Yoshinobu Kubota
Affiliation:
Keywords: Angiotensin II, renin-angiotensin system, angiotensin II receptor blocker, prostate cancer, hormone-refractorycancer
Abstract: It is known that the renin-angiotensin system (RAS) plays a fundamental role not only as a vasoconstrictor incontrolling blood pressure and electrolyte/fluid homeostasis, but also as a mitogenic factor through the Ang-II type-1(AT1) receptor in smooth muscle cells and cardiac myocytes. Angiotensin II (Ang-II) is indeed thought to be a growthfactor, and Ang-II receptor blockers (ARBs), a class of antihypertensive agent, suppress signal transduction pathwaysmediated by several growth factors or cytokines, through the AT1 receptor. There is increasing evidence that the RAS isimplicated in the development of various cancers. We previously demonstrated that ARBs have the potential to inhibit thegrowth of prostate cancer cells and tumors through the AT1 receptor. This review highlights the possibility of ARBs asnovel agents for prostate cancer as well as other cancers, and reviews the literature on this area.
Export Options
About this article
Cite this article as:
Uemura Hiroji, Ishiguro Hitoshi and Kubota Yoshinobu, Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer, Mini-Reviews in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/138955706777698633
DOI https://dx.doi.org/10.2174/138955706777698633 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Zebrafish: A Complete Animal Model for In Vivo Drug Discovery and Development
Current Drug Metabolism Cancer and Stem Cells
Current Cancer Therapy Reviews Nanoparticles for Cancer Targeting: Current and Future Directions
Current Drug Delivery Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Ghrelin and Energy Balance: Focus on Current Controversies
Current Drug Targets Role of TGF-β in Melanoma
Current Pharmaceutical Biotechnology Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Current Pharmaceutical Design A Highly Sensitive Chemiluminescence Method and Application in Rapid Pharmacokinetic Study of Matrine in Rat Plasma
Current Pharmaceutical Analysis Testicular Cell Junction: A Novel Target for Male Contraception
Current Medicinal Chemistry Rhenium-188 and Copper-67 Radiopharmaceuticals for the Treatment of Bladder Cancer
Mini-Reviews in Medicinal Chemistry Editorial [ Hot Topic:Emerging Anticancer Effects of Antiresorptive Therapies (Guest Editor: Vera Hirsh)]
Anti-Cancer Agents in Medicinal Chemistry Antitumor Activity of Titanocene Y in Xenografted PC3 Tumors in Mice
Letters in Drug Design & Discovery Recurrent Rearrangements in Prostate Cancer: Causes and Therapeutic Potential
Current Drug Targets Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Does Ligand Symmetry Play a Role in the Stabilization of DNA G-Quadruplex Host-Guest Complexes?
Current Medicinal Chemistry The Effects of 1,3,5-trisubstituted Indole Derivatives on Cell Growth, Apoptosis and MMP-2/9 mRNA Expression of MCF-7 Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents
Current Cancer Drug Targets Synthesis of Pyridine and Spiropyridine Derivatives Derived from 2-aminoprop- 1-ene-1,1,3-tricarbonitrile Together with their c-Met Kinase and Antiproliferative Evaluations
Anti-Cancer Agents in Medicinal Chemistry Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells
Current Pharmaceutical Design